We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
Cap. Flow
+$12.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$36.1M
3
SNY icon
Sanofi
SNY
+$34.1M
4
CYTK icon
Cytokinetics
CYTK
+$31.4M
5
WAT icon
Waters Corp
WAT
+$25.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$147M
2
PTCT icon
PTC Therapeutics
PTCT
+$72.4M
3
IMVT icon
Immunovant
IMVT
+$55.7M
4
DDOG icon
Datadog
DDOG
+$31.8M
5
AVNS
Avanos Medical
AVNS
+$28M

Sector Composition

Rank Sector Weight
1 Miscellaneous 55.89%
2 Healthcare 30.09%
3 Technology 6.58%
4 Consumer Discretionary 3.42%
5 Communication Services 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
26
CALL
Immunovant
IMVT
$8.11B
$46.2M 0.57%
1,200,000
-700,000
-37% -$21.3M
SNY icon
27
Sanofi
SNY
$106B
$45.4M 0.56%
1,064,000
+764,000
+255% +$34.1M
IMCR icon
28
Immunocore
IMCR
$1.86B
$45.3M 0.55%
1,428,000
+240,000
+20% +$7.1M
GOOGL icon
29
Alphabet (Google) Class A
GOOGL
$4.14T
$45.2M 0.55%
126,494
+7,980
+7% +$2.87M
SLDB icon
30
Solid Biosciences
SLDB
$1.1B
$42.7M 0.52%
4,278,000
+1,078,000
+34% +$8.17M
MDB icon
31
MongoDB
MDB
$29.7B
$42M 0.51%
125,172
+17,876
+17% +$5.36M
KURA icon
32
Kura Oncology
KURA
$1.18B
$40.3M 0.49%
3,678,000
-58,000
-2% -$547K
XRAY icon
33
Dentsply Sirona
XRAY
$2.27B
$39M 0.48%
3,672,000
+672,000
+22% +$7.34M
UBER icon
34
Uber
UBER
$155B
$35.9M 0.44%
497,908
-20,852
-4% -$1.53M
AXGN icon
35
Axogen
AXGN
$2.6B
$35.8M 0.44%
775,000
-161,000
-17% -$6.49M
IRON icon
36
Disc Medicine
IRON
$3.04B
$33.6M 0.41%
460,000
-76,000
-14% -$5.22M
GTLB icon
37
GitLab
GTLB
$8.3B
$32.8M 0.4%
1,074,141
+45,477
+4% +$1.15M
FIVN icon
38
FIVE9
FIVN
$2.49B
$32.7M 0.4%
1,536,000
-56,000
-4% -$1.11M
HUBS icon
39
HubSpot
HUBS
$12.3B
$32.5M 0.4%
178,047
+49,464
+38% +$10.3M
ALGN icon
40
Align Technology
ALGN
$11.3B
$30.4M 0.37%
180,286
+22,327
+14% +$3.88M
MSFT icon
41
Microsoft
MSFT
$3.71T
$30.1M 0.37%
80,581
+31,721
+65% +$12.8M
OFIX icon
42
Orthofix Medical
OFIX
$378M
$29.8M 0.37%
3,264,000
+564,000
+21% +$6.22M
HUM icon
43
Humana
HUM
$48.2B
$28.8M 0.35%
72,527
-68,752
-49% -$19.6M
ANGO icon
44
AngioDynamics
ANGO
$628M
$28.6M 0.35%
2,198,000
+329,000
+18% +$3.74M
TVTX icon
45
CALL
Travere Therapeutics
TVTX
$6.15B
$28.4M 0.35%
+500,000
New +$22.2M
WAT icon
46
Waters Corp
WAT
$40.2B
$28.1M 0.34%
+75,004
New +$25.6M
MLYS icon
47
CALL
Mineralys Therapeutics
MLYS
$2.49B
$28.1M 0.34%
+1,040,000
New +$28.5M
S icon
48
CALL
SentinelOne
S
$6.92B
$27.2M 0.33%
1,600,000
-50,000
-3% -$769K
VSTM icon
49
Verastem
VSTM
$743M
$26.8M 0.33%
7,024,000
+2,432,000
+53% +$11.8M
FDMT icon
50
4D Molecular Therapeutics
FDMT
$827M
$26.6M 0.33%
2,000,000
– –
1
2
3 4 5

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.

  • Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
  • Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
  • Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
  • Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
  • Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
  • Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.